New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 16, 2014
06:02 EDTAKERAkers Biosciences signs agreements to market rapid tests in India
Akers Biosciences entered into an agreement with Jai Capital, a Nevada company specializing in market development, distribution, and joint ventures of medical devices in India, to market the company's PIFA Heparin/Platelet Factor-4 Rapid Assay, PIFA Dengue Assay, Battlefield Blood Transfusion Card and Tri-Cholesterol rapid tests. Limited initial sales to the military are expected to enable the military to carry out evaluations of the products. The Directors believe that military approval, if obtained, is likely to occur in the second half of the current financial year. Secondly, Jai will seek to forge one or more strategic partnerships with Indian medical diagnostic companies. It is the Directors' opinion that, if formed, these partnerships may help to facilitate a faster approval process for the Company's tests with the Indian Government and as such it is expected that the approval process will start in due course in the event that such strategic partnerships are formed. Unlike with the military, these approvals are necessary to sell the Company's products into the insurance and medical marketplaces in India.
News For AKER From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 28, 2015
07:12 EDTAKERRedChip Companies to hold a virtual conference
Subscribe for More Information
January 26, 2015
07:10 EDTAKERAkers Biosciences granted European patent for blood separator technology
Akers Biosciences announces that the European Patent Office has issued a patent surrounding the company's novel blood separator technology and method of separating a fluid fraction from whole blood. Akers was granted U.S. patent protection for the Technology in 2011. The Technology, developed and wholly owned by Akers, enables rapid blood cell separation of small volumes of whole blood, including those obtained from finger stick samples. By utilizing the Technology, serum or plasma samples are extracted within 30-90 seconds and are ready for immediate analysis. By contrast, conventional methods of blood cell separation are labor-intensive and time consuming, taking 30-120 minutes, and typically involving blood collection and laboratory personnel as well as electrically-powered centrifuges and other specialized equipment. The Technology, which further accelerates the rate at which a test result is obtained, is marketed by Akers under the brand name seraSTAT and forms a key component of the company's PIFA product range. In addition to seraSTAT's incorporation within some of the company's own diagnostic tests, Akers intends to license its proprietary blood separator Technology to third parties seeking to accelerate their own testing procedures by facilitating the blood cell separation process as a component of their test.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use